Target Acquired, Protein Deleted: The Next Frontier in Precision Medicine and IP Strategy – March 2026 Update

Michael Ellenberger, Aydin Harston Ph.D., Stephanie Waltersdorff
Rothwell, Figg, Ernst & Manbeck, P.C.
Contact
LinkedIn
Facebook
X
Send
Embed

Targeted protein degradation (TPD) has moved from promising concept to near-commercial reality in under a decade. By hijacking the cell’s ubiquitin-proteasome system, TPD therapies eliminate disease-driving proteins entirely rather than merely inhibiting them. This approach is particularly powerful against “undruggable” targets that lack deep binding pockets. PROTACs (proteolysis-targeting chimeras) and molecular glues remain the most clinically advanced modalities, but LYTACs (lysosome-targeting chimeras), AUTACs (autophagy-targeting chimeras), DUBTACs (deubiquitinase-targeting chimeras), and degrader-antibody conjugates (DACs) are advancing rapidly.

Parallel to the scientific maturation, patent filings, including those covering E3 ligase binders, bifunctional scaffolds, linkers, and mechanisms of degradation, have expanded significantly, creating a layered and increasingly competitive patent environment.

We previously examined targeted protein degradation (TPD) as an emerging frontier in precision medicine. Since then, the field has materially accelerated as large-pharma collaborations have expanded in scale, late-stage assets shift commercialization strategies, and M&A activity reflects that protein degraders are now core pipeline priorities.

Here we provide updates on patent activity, recent transactions, clinical developments across PROTACs and molecular glues, and evolving partnership and IP considerations shaping the TPD landscape in early 2026.

The IP landscape surrounding targeted protein degradation has evolved as rapidly as the science. Early patent activity in the field focused on foundational platform IP, including bifunctional molecule scaffolds, E3 ligase recruiting ligands (e.g., cereblon, VHL, IAP), linker chemistry, and general methods of inducing ubiquitination and proteasomal degradation. Those early filings now form the backbone of a dense and increasingly overlapping patent landscape.

As clinical assets advance, the focus for IP filers has shifted toward layered protection strategies including:

  • Composition-of-matter claims directed to specific degrader molecules and defined linkers.
  • Genus claims covering structurally-related degraders targeting the same protein.
  • Target-specific degradation methods tied to defined E3 ligases.
  • Formulation, dosing, and combination therapy claims designed to extend lifecycle protection.
  • Platform claims directed to screening technologies, proteomics approaches, and induced-proximity mechanisms.

Patent filings in the TPD space have grown steadily over the past decade, with published U.S. and PCT applications increasing materially year-over-year between 2020 and 2025, with no signs of slowing in early 2026.[1] In fact, there are already more application publications in the first quarter of 2026 than the total number of publications in 2020.[2] Landscape analyses have identified hundreds of patent families directed to PROTACs and bifunctional degraders alone, underscoring the breadth of active assignees and the competitive intensity of this area.

As a snapshot, the assignees with the most published patent families in the TPD space since 2024 are shown below:[3]

Rank Optimized Assignee # of Patent Families
1 ROCHE HOLDING LTD. 14
2 CHINESE ACADEMY OF SCIENCE 13
3 C4 THERAPEUTICS INC 11
4 YALE UNIVERSITY 11
5 UNIVERSITY OF CALIFORNIA 10
6 INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE 9
7 MONTE ROSA THERAPEUTICS AG 9
8 DANA-FARBER CANCER INSTITUTE (INC.) 8
9 HANGZHOU ZHONGMEI HUADONG PHARM CO LTD 8
10 MERCK & CO. INC. 8

For molecular glues, the IP analysis presents distinct challenges. Many next-generation cereblon modulators must be differentiated from legacy immunomodulatory imide drug (IMiD) estates, which can require careful claim drafting. Functional claiming tied to induced proximity also raises enablement and written description considerations, as courts increasingly scrutinize broad genus claims, even in the small-molecule context.

The result is a patent environment that is no longer driven mainly by invention, but also by freedom-to-operate concerns. To succeed, companies must evaluate:

  • The breadth and enforceability of early foundational patent families;
  • Competing linker and scaffold coverage;
  • Target-specific degradation claims filed by early movers;
  • Potential post-grant challenges to broad foundational filings, particularly broad functionally-claimed molecules; and
  • Jurisdiction-specific differences in claim interpretation and exclusivities.

Accordingly, IP strategy in TPD has shifted from offensive filing to proactive portfolio management, e.g., by integrating offensive and defensive prosecution strategies, transaction structuring including licensing and acquisitions, proactive patent challenges, and litigation readiness into core development planning.

In the last year, new PROTACs and molecular glues have entered development and there have been several updates to those already in development.

PROTACs

As for new PROTACs in development, Amgen acquired Dark Blue Therapeutics Ltd., adding the MLLT1/3 degrader to Amgen’s portfolio. According to Jay Bradner, M.D., executive vice president of Research and Development at Amgen, “[t]his acquisition complements and extends our research in targeted protein degradation and leukemia therapeutics, advancing our strategy to invest early in rising medicines for novel therapeutic targets. The adjacency of this program to our considered expertise in cancer biology will propel MLLT1/3-targeting medicines to clinical investigation for patients facing the challenging diagnosis of AML.”[4]

Beyond pipeline expansion, acquisitions of first-in-class degraders may secure control over composition-of-matter claims and target-specific degradation patent estates, which can define exclusivity boundaries for follow-on entrants targeting the same protein. 

While many of the clinical trials are still active and ongoing, others are now complete. An updated version of PROTACs in development are listed below:

Name Company Description Clinical Trials
ARV-471 Vepdegestrant[5] Arvinas & Pfizer An estrogen receptor (ER) degrader for hormone-receptor-positive breast cancer Phase III trials (NCT05654623) – active[6]
ARV-110 Bavdegalutamide[7] Arvinas An androgen receptor (AR) degrader for prostate cancer Phase II trials (NCT03888612) – completed[8]
ARV-766[9] Arvinas An androgen receptor (AR) degrader treating metastatic castration-resistant prostate cancer Phase II trials (NCT05067140) – active[10]
NX-2127[11] Nurix A BTK degrader for B-cell malignancies Phase I trials (NCT04830137) – recruiting[12]
KT-333[13] Kymera Selective degradation of the transcriptional regulator signal transducer and activator of transcription 3 (STAT3) for treating peripheral T-cell lymphoma, cutaneous T-cell lymphoma, large granular lymphocytic leukemia, and solid tumors Phase I trials (NCT05225584) – completed[14]
HSK29116[15] Haisco Pharmaceutical Bruton tyrosine kinase-targeting for treating relapsed or refractory B-cell malignancies Phase I trials (NCT04861779) – status unknown[16]
MLLT 1/3 Degrader[17] Amgen (via Dark Blue Therapeutics) First-in-class small molecule degrader of the transcriptional regulator, MLLT 1/3, for use as monotherapy and as backbone in combination therapy in patients with AML, solid cancers IND enabling studies
BMS-986365 Celgene (acquired by Bristol Myers Squibb) Compare efficacy and safety of BMS-986365 compared to investigator’s choice of therapy for treating metastatic castration-resistant prostate cancer Phase III trials (NCT06764485) – recruiting[18]
BGB-16673 BeOne Medicines (formerly BeiGene) Recommended dosing exploration for BGB-16673. Phase I and II trials (NCT05006716) – recruiting[19]
DT2216 Dana-Farber Cancer Institute & U.S. Department of Defense & Dialectic Therapeutics & American Society of Clinical Oncology DT2216 and Paclitaxel in treating platinum-resistant ovarian cancer Phase I trials (NCT06964009) – recruiting[20]

Molecular Glues

The majority of clinical trials for molecular glues remain active. In addition, SEED Therapeutics has entered clinical trials with its molecular glue and announced, “the dosing of the first patient in its Phase 1a dose-escalation study of ST-01156, an oral RMB39 degrader, in patients with advanced solid tumors.”[21]

As next-generation molecular glues advance, patent strategy increasingly turns on differentiation from legacy patent estates, such as those directed to cereblon-modulation. Structural changes, altered substrate specificity, or new mechanistic distinctions are central both to patentability and freedom-to-operate analyses.   

An updated table of examples of molecular glues that are FDA-approved or in development is shown below:

Name Company Description Clinical Trials
CC-90009[22] Bristol Myers Squibb A cereblon-binding molecular glue targeting GSPT1, in clinical trials for acute myeloid leukemia (AML) Phase I trial terminated due to lack of efficacy in the short-term acute phase (NCT02848001)
dBET1[23] Dana-Farber Cancer Institute & C4 Therapeutics A BRD4 degrader that recruits cereblon to induce degradation Preclinical
Lenalidomide (Revlimid)[24] Bristol Myers Squibb Originally developed as an immunomodulator, later shown to function as a molecular glue that induces degradation of IKZF1 and IKZF3, transcription factors critical in multiple myeloma FDA approved
Thalidomide[25] Bristol Myers Squibb The first immunomodulatory drug (IMiD) shown to induce degradation of IKZF1 and IKZF3 via cereblon; used in multiple myeloma and erythema nodosum leprosum FDA approved
Pomalidomide (Pomalyst)[26] Bristol Myers Squibb Another IMiD acting as a molecular glue targeting IKZF1 and IKZF3 in multiple myeloma FDA approved
CC-122[27] Bristol Myers Squibb A next-generation cereblon modulator targeting IKZF1, IKZF3, and ZFP91; in clinical trials for lymphoma and solid tumors. Phase I trial completed (NCT01421524) for patients with advanced solid Tumors, non-Hodgkin’s Lymphoma, or Multiple Myeloma
Iberdomide (CC-220)[28] Bristol Myers Squibb/Celgene Targets IKZF1, IKZF3, ZFP91, and ZNF98; in trials for relapsed/refractory multiple myeloma and systemic lupus erythematosus. Phase II trial targeting IKZF1/3 for treatment of RRMM (NCT04975997) – active[29]
CC-99282[30] Bristol Myers Squibb A cereblon modulator targeting IKZF1 and IKZF3 In development for B-cell lymphomas (NCT03930953) – active[31]
CC-92480[32] Bristol Myers Squibb IKZF1/3 degrader In trials for multiple myeloma and non-Hodgkin lymphoma (NHL) (NCT03989414) – active[33]
DKY-709[34] Novartis Targets IKZF2 Phase I trials for solid tumors, alone or in combination with checkpoint inhibitors (NCT03891953) – active[35]
ST-01156 SEED Therapeutics Orally administered, brain-penetrant molecular glue degrader designed to selectively degrade RBM39, a key regulator of RNA splicing and transcription required for the survival of several cancer types Phase I trials (NCT07197554)

Biotechnology and pharmaceutical companies continue to actively pursue TPD therapies.  Companies with notable programs in the TPD field are provided in the updated table below.

Company Key Focus Notable Programs Collaborations
Arvinas PROTACs ARV-471 (ER degrader), ARV-110 (AR degrader) Novartis[36] Pfizer[37]
Foghorn Therapeutics PROTACs (BRD9 Degraders) FHD-609[38], FHD-909 Eli Lilly
Monte Rosa Therapeutics Molecular glues MRT-6160 (T and B cell-modulating VAV1-directed molecular glue degraders) Novartis[39]
Nurix Therapeutics E3 ligase modulation, PROTACs GS-6791 (previously NX-0479; IRAK4 degrader) NX-2127 (BTK degrader) NX-5948 (BTK degrader) STAT6 signal transducer and activator of transcription Gilead[40] Sanofi[41] Seagen[42]
Kymera Therapeutics PROTACs KT-474 (IRAK4 degrader) Sanofi[43] Vertex[44]
C4 Therapeutics PROTACs BiDAC platform CFT7455 (IKZF1/3 degrader) Utilize TORPEDO platform to discover degraders Biogen[45] Merck[46] Betta Pharma[47]
Bristol Myers Squibb (BMS) Molecular glues CC-90009, Revlimid Celgene IP estate[48]
Novartis Molecular glues, PROTACs Targeting undrugged proteins Dunad Therapeutics[49]
Pfizer, Merck, Roche Various TPD strategies Internal discovery programs External licensing
SEED Therapeutics Molecular glues, Tau degrader ST-01156 Eli Lilly, Eisai[50]
EpiBiologics Combination therapies including bispecific antibodies with degraders EpiTAC; undisclosed discovery programs Johnson & Johnson, Google Ventures[51]
Amgen PROTACs, molecular glues Acquisition of Dark Blue Therapeutics Ltd. M&A[52]

As we outlined in our prior post on TPD, because TPD is an innovative therapeutic approach, numerous strategic partnerships and licensing agreements are aimed at advancing TPD technologies. Below we discuss (a) updates to existing deals and collaborations, (b) new licensing deals and collaborations, (c) upcoming milestones in existing collaborations, and (d) licensing deals and collaborations with no significant updates. Many of these agreements reflect not just scientific collaboration, but access to platform intellectual property, field-of-use exclusivity, and risk allocation tied to patent term and portfolio strength.

Updates to Existing Deals and Collaborations

In September 2025, Arvinas and Pfizer provided an update on their collaboration for the development of vepdegestrant, an oral PROTAC estrogen receptor protein degrader. Specifically, the collaborators agreed to out-license the vepdegestrant commercialization rights to a third party. Arvinas and Pfizer seek a party “with the capabilities and expertise to maximize the commercial potential of vepdegestrant, if approved, for patients with ESR1-mutant, ER+/HER2-advanced or metastatic breast cancer and potentially develop vepdegestrant in new settings.”[53]

Also in September 2025, Monte Rosa and Novartis announced their collaboration on a second deal for accelerating the development of molecular glue degrader for immune-mediated diseases.[54]

Parties IP/Asset Focus Description of Licensing Deal
Arvinas and Pfizer[55] ARV-471 (AR degrader) Vepdegestrant In September 2025, Arvinas and Pfizer agreed to out-license the commercialization rights to vepdegestrant to a third party.[56] The Arvinas investigational PROTAC degraders currently in Phase 1 trials are: ARV-102 (LRRK2 degrader), ARV-393 (BCL6 degrader), and ARV-806 (KRAS G12D degrader).   In August 2025, the FDA accepted the New Drug Application (NDA) for ARV-47, or vepdegestrant. The NDA submission was based on a Phase 3 trial.[57]   In 2021, Arvinas partnered with Pfizer to develop and commercialize ARV-471, an oral estrogen receptor protein degrader for breast cancer. Arvinas received an upfront payment and is eligible for up to $1.4 billion in milestones, sharing profits and costs equally. 
Monte Rosa Therapeutics and Novartis[58] MRT-6160 and other VAV1 molecular glue degraders In September 2025, Monte Rosa and Novartis entered a second deal focused on accelerating development of molecular glue degrader for immune-mediated diseases.   In October 2024, Novartis agreed to pay Monte Rosa Therapeutics $150 million upfront for a global license to develop molecular glue degraders, with potential future payments up to $2.1 billion and royalties on non-U.S. sales. 

New Licensing Deals

A few new deals have recently been announced. In June 2025, Gilead Sciences and Kymera Therapeutics entered into an exclusive option and license agreement for the development and acceleration of a novel molecular glue degrader targeting cyclin-dependent kinase 2 (CDK2) with the potential for broad oncology treatment including in breast cancer and other solid tumors.[59]

Although not a formal licensing deal, the UK’s Institute of Cancer Research (ICR) Centre for Protein Degradation and NEOsphere Biotechnologies announced a research collaboration on October 2, 2025, aimed at accelerating molecular glue degrader discovery.[60] 

Parties IP/Asset Focus Description of Licensing Deal or Collaboration
Kymera Therapeutics and Gilead Sciences[61] Cyclin-dependent kinase 2 (CDK2)-directed molecular glue degraders (MGD) In June 2025, Kymera and Gilead entered into an exclusive option and license agreement to accelerate the development of the novel CDK2-directed MGDs. Kymera will lead the research activities for the program and Gilead has the right to exercise an option to exclusively license the program. Kymera is eligible to receive up to $750 million in payments, including several million dollars for upfront and potential option exercise payments.
Institute of Cancer Research (ICR) Centre for Protein Degradation and NEOsphere Biotechnologies[62] Molecular glues Using high-throughput proteomics to rapidly assess proteome-wide effects of compound modifications, enabling faster iteration and more efficient refinement of promising molecular glue degrader drug candidates.

Upcoming Milestones in Existing Licensing Deals

The C4 Therapeutics and Betta Pharmaceuticals deal has not yet had significant updates, but CFT8919, the EGFR degrader for non-small-cell lung cancer, is set to use data from the Phase 1 trial to inform potential ex-China clinical development by the end of Q1 2026.[63]

Parties IP/Asset Focus Description of Licensing Deal
C4 Therapeutics and Betta Pharmaceuticals[64] CFT8919 (EGFR degrader, China) End of Q1 2026: Data from Phase 1 trial will be used to inform potential ex-China clinical development.   In May 2023, C4 Therapeutics partnered with Betta Pharmaceuticals for the development and commercialization of CFT8919 in Greater China. The deal involved a $10 million upfront payment, a $25 million equity investment, and up to $357 million in potential milestones, plus royalties. 

No Significant Updates to Licensing Deals and Collaborations

Deals involving (a) Nurix Therapeutics and Sanofi, (b) Arvinas and Novartis, (c) Kymera and Vertex, (d)  Vividion and Roche, (e) C4 Therapeutics and Merck, (f) Gilead and Nurix, and (g) Seagen (now Pfizer) and Nurix have not announced significant updates, but there is no indication that the deals have ceased.

Parties IP/Asset Focus Description of Licensing Deal
Nurix Therapeutics and Sanofi[65] E3 ligase modulators In April 2025, Nurix extended its collaboration with Sanofi, focusing on a novel transcription factor for autoimmune diseases. Nurix received a $15 million extension fee, bringing the total received to $105 million, with potential for up to $465 million in future milestones per licensed program, plus royalties. 
Arvinas and Novartis[66] ARV-766 (AR degrader) In April 2024, Arvinas licensed its Phase 3-ready protein degrader, ARV-766, to Novartis for an upfront payment of $150 million. The agreement includes potential milestones up to $1.01 billion and tiered royalties. 
Kymera Therapeutics and Vertex Pharmaceuticals[67] Undisclosed degrader targets In 2019, Kymera entered a four-year collaboration with Vertex, receiving $70 million upfront, including an equity investment. The partnership aims to develop protein degradation drugs for serious diseases, with potential deal value exceeding $1 billion. 
Vividion Therapeutics and Roche[68] E3 ligases and select oncology targets In May 2020, Vividion inked a deal with Roche, receiving $135 million upfront to utilize its proteomics screening platform for discovering novel E3 ligases, with potential for several billion dollars in milestone payments and royalties. 
C4 Therapeutics and Merck KGaA[69] Targeted protein degraders under C4 TORPEDO platform In March 2024, C4 Therapeutics announced a collaboration with Merck KGaA to develop targeted protein degraders for oncogenic proteins. C4T received a $16 million upfront payment, with Merck covering discovery research costs. 
Nurix Therapeutics and Gilead Sciences[70] IRAK4 degraders including GS-6791 Nurix and Gilead extended their collaboration in 2024 for an additional two years, focusing on developing targeted protein degraders. Gilead paid a $15 million extension fee, aiming to advance multiple degrader programs. 
Seagen and Nurix Therapeutics[71] Two unnamed products based on Nurix DELigase platform In September 2023, Nurix and Seagen initiated a strategic collaboration to develop Degrader-Antibody Conjugates (DACs), combining targeted protein degradation with antibody-drug conjugation to selectively kill cancer cells. 

As first-generation degraders approach late-stage development, companies are increasingly focused on exclusivity duration. Follow-on degraders with modified ligase recruiters, optimized linkers, alternative binding epitopes, improved oral bioavailability, or enhanced CNS penetration may support new composition-of-matter protection and extend effective exclusivity horizons. Simultaneously, combination approaches, including degrader-antibody conjugates and multi-modal constructs, likewise create opportunities for secondary filings that augment core platform patents and extend exclusivity.

Targeted protein degradation (TPD) continues to redefine the boundaries of drug discovery, offering transformative solutions for previously intractable diseases. With PROTACs, molecular glues, and emerging modalities like DUBTACs and LYTACs driving clinical successes, the TPD market is on track to explode higher. Yet, this promise comes with challenges: navigating a dense patent landscape, securing freedom to operate, and overcoming scientific and regulatory hurdles require strategic precision.  As the TPD field accelerates, partnering with the patent counsel with subject matter expertise is critical to staying ahead.

[1] Search of Derwent database March 2026 (INPADOC family count and publication year results generated using the keyword query: (CTB=((protein ADJ degrad*) OR (PROTAC OR proteolysis ADJ target* ADJ chimera) OR “molecular glue” OR (LYTAC OR lysosome ADJ target* ADJ chimera) OR (AUTAC OR autophagy ADJ target* ADJ chimera) OR (ATTEC OR autophagy ADJ teth* ADJ compound))) AND (AD>=(20200101)) AND (CC=(US OR WO)).

[2] Id.

[3] Search of Derwent database March 2026 (INPADOC family count and publication year results generated using the keyword query: (CTB=((protein ADJ degrad*) OR (PROTAC OR proteolysis ADJ target* ADJ chimera) OR “molecular glue” OR (LYTAC OR lysosome ADJ target* ADJ chimera) OR (AUTAC OR autophagy ADJ target* ADJ chimera) OR (ATTEC OR autophagy ADJ teth* ADJ compound))) AND (AD>=(20240101)) AND (CC=(US OR WO)); sorted by Optimized Assignee.

[4] Id.

[5] Tan, Xueqiang, et al. “Molecular glue-mediated targeted protein degradation: A novel strategy in small-molecule drug development.” Iscience (2024).

[6] https://clinicaltrials.gov/study/NCT05654623?cond=NCT05654623&rank=1

[7] Tan et al.

[8] https://clinicaltrials.gov/study/NCT03888612

[9] Tan et al.

[10] https://clinicaltrials.gov/study/NCT05067140

[11] Danilov, Alexey, et al. “A first-in-Human phase 1 trial of NX-2127, a first-in-class Bruton’s Tyrosine Kinase (BTK) dual-targeted protein degrader with immunomodulatory activity, in patients with relapsed/refractory B cell malignancies.” Blood 142 (2023): 4463.

[12] https://clinicaltrials.gov/study/NCT04830137

[13] Tan et al.

[14] https://clinicaltrials.gov/study/NCT05225584

[15] Tan et al.

[16] https://clinicaltrials.gov/study/NCT04861779

[17] https://www.darkbluetx.com/our-science#pipeline

[18] https://clinicaltrials.gov/study/NCT06764485

[19] https://clinicaltrials.gov/study/NCT05006716

[20] https://clinicaltrials.gov/study/NCT06964009

[21] https://www.seedtherapeutics.com/media/seed-therapeutics-doses-first-patient-in-phase-1-trial-of-st-01156-a-molecular-glue-degrader-targeting-rbm39-2

[22] Hansen, Joshua D., et al. “CC-90009: a cereblon E3 ligase modulating drug that promotes selective degradation of GSPT1 for the treatment of acute myeloid leukemia.” Journal of medicinal chemistry 64.4 (2021): 1835-1843.

[23] Liu, Lei, et al. “Targeted BRD4 protein degradation by dBET1 ameliorates acute ischemic brain injury and improves functional outcomes associated with reduced neuroinflammation and oxidative stress and preservation of blood–brain barrier integrity.” Journal of neuroinflammation 19.1 (2022): 168.

[24] Yamanaka, Satoshi, et al. “Lenalidomide derivatives and proteolysis-targeting chimeras for controlling neosubstrate degradation.” Nature communications 14.1 (2023): 4683.

[25] Oleinikovas, Vladas, et al. “From thalidomide to rational molecular glue design for targeted protein degradation.” Annual review of pharmacology and toxicology 64.1 (2024): 291-312.

[26] Sasso, Janet M., et al. “Molecular glues: the adhesive connecting targeted protein degradation to the clinic.” Biochemistry 62.3 (2022): 601-623.

[27] Id.

[28] Id.

[29] https://clinicaltrials.gov/study/NCT04975997

[30] Sasso et al.

[31] https://clinicaltrials.gov/study/NCT03930953

[32] Hansen, Joshua D., et al. “Discovery of CRBN E3 ligase modulator CC-92480 for the treatment of relapsed and refractory multiple myeloma.” Journal of medicinal chemistry 63.13 (2020): 6648-6676.

[33] https://www.bmsclinicaltrials.com/us/en/clinical-trials/NCT03989414

[34] Hansen et al.

[35] https://clinicaltrials.gov/study/NCT03891953

[36] https://ir.arvinas.com/news-releases/news-release-details/arvinas-enters-transaction-novartis-including-global-license

[37] https://www.pfizer.com/news/press-release/press-release-detail/arvinas-and-pfizer-announce-global-collaboration-develop

[38] https://foghorntx.com/wp-content/uploads/2023/04/Netherton_DDC_2023_presentation.pdf

[39] https://ir.monterosatx.com/news-releases/news-release-details/monte-rosa-therapeutics-announces-global-license-agreement; https://ir.monterosatx.com/news-releases/news-release-details/monte-rosa-therapeutics-announces-collaboration-novartis

[40] https://ir.nurixtx.com/news-releases/news-release-details/nurix-therapeutics-outlines-2025-goals-and-objectives

[41] https://ir.nurixtx.com/news-releases/news-release-details/nurix-therapeutics-announces-extension-strategic-collaboration-0

[42] https://ir.nurixtx.com/news-releases/news-release-details/nurix-announces-strategic-collaboration-seagen-combining

[43] https://investors.kymeratx.com/news-releases/news-release-details/kymera-announces-expansion-kt-474-sar444656-hs-and-ad-phase-2

[44] https://investors.vrtx.com/news-releases/news-release-details/vertex-and-kymera-therapeutics-establish-strategic-collaboration

[45] https://ir.c4therapeutics.com/news-releases/news-release-details/c4-therapeutics-announces-delivery-second-development-candidate

[46] https://ir.c4therapeutics.com/news-releases/news-release-details/c4-therapeutics-announces-strategic-discovery-research

[47] https://ir.c4therapeutics.com/news-releases/news-release-details/c4-therapeutics-and-betta-pharmaceuticals-announce-exclusive

[48] https://news.bms.com/news/details/2019/Bristol-Myers-Squibb-to-Acquire-Celgene-to-Create-a-Premier-Innovative-Biopharma-Company/default.aspx

[49] https://www.biospace.com/novartis-strikes-1-3-billion-deal-with-protein-degradation-startup-dunad-therapeutics

[50] https://www.seedtherapeutics.com/media/seed-therapeutics-completes-30-million-series-a-3-financing; https://beyondspringpharma.com/beyondspring-subsidiary-seed-therapeutics-announces-research-collaboration-and-license-agreement-with-lilly/

[51] https://www.fiercebiotech.com/biotech/jj-gv-line-back-protein-degradation-biotech-epibiologics-107m-series-b

[52] https://www.amgen.com/newsroom/press-releases/2026/01/amgen-acquires-dark-blue-therapeutics-bolstering-oncology-pipeline.

[53] https://ir.arvinas.com/news-releases/news-release-details/arvinas-provides-update-collaboration-pfizer-and-announces

[54] https://ir.monterosatx.com/news-releases/news-release-details/monte-rosa-therapeutics-announces-collaboration-novartis

[55] https://www.pfizer.com/news/press-release/press-release-detail/arvinas-and-pfizer-announce-global-collaboration-develop

[56] https://ir.arvinas.com/news-releases/news-release-details/arvinas-provides-update-collaboration-pfizer-and-announces

[57] https://ir.arvinas.com/news-releases/news-release-details/arvinas-announces-fda-acceptance-new-drug-application

[58] https://ir.monterosatx.com/news-releases/news-release-details/monte-rosa-therapeutics-announces-closing-global-license

[59] https://investors.kymeratx.com/news-releases/news-release-details/gilead-sciences-and-kymera-therapeutics-enter-exclusive-option

[60] https://www.icr.ac.uk/about-us/icr-news/detail/icr-centre-for-protein-degradation-and-neosphere-biotechnologies-announce-research-collaboration–to-discover-new-molecular-glue-degrader-therapeutics

[61] https://investors.kymeratx.com/news-releases/news-release-details/gilead-sciences-and-kymera-therapeutics-enter-exclusive-option

[62] https://www.icr.ac.uk/about-us/icr-news/detail/icr-centre-for-protein-degradation-and-neosphere-biotechnologies-announce-research-collaboration–to-discover-new-molecular-glue-degrader-therapeutics

[63] https://www.biospace.com/press-releases/c4-therapeutics-reports-fourth-quarter-and-full-year-2025-financial-results-and-recent-business-highlights

[64] https://ir.c4therapeutics.com/news-releases/news-release-details/c4-therapeutics-and-betta-pharmaceuticals-announce-exclusive

[65] https://ir.nurixtx.com/news-releases/news-release-details/nurix-licenses-drug-discovery-program-sanofi-targeting-novel

[66] https://ir.arvinas.com/news-releases/news-release-details/arvinas-enters-transaction-novartis-including-global-license

[67] https://investors.vrtx.com/news-releases/news-release-details/vertex-and-kymera-therapeutics-establish-strategic-collaboration

[68] https://vividion.com/news/vividion-therapeutics-announces-drug-discovery-collaboration-with-roche-focused-on-novel-e3-ligases/

[69] https://ir.c4therapeutics.com/news-releases/news-release-details/c4-therapeutics-announces-strategic-discovery-research

[70] https://ir.nurixtx.com/news-releases/news-release-details/nurix-therapeutics-announces-extension-strategic-collaboration

[71] https://ir.nurixtx.com/news-releases/news-release-details/nurix-announces-strategic-collaboration-seagen-combining

Send Print Report

DISCLAIMER: Because of the generality of this update, the information provided herein may not be applicable in all situations and should not be acted upon without specific legal advice based on particular situations. Attorney Advertising.

© Rothwell, Figg, Ernst & Manbeck, P.C.

Written by:

Rothwell, Figg, Ernst & Manbeck, P.C.
Rothwell, Figg, Ernst & Manbeck, P.C.
Contact
more
less

PUBLISH YOUR CONTENT ON JD SUPRA

  • ✔ Increased readership
  • ✔ Actionable analytics
  • ✔ Ongoing writing guidance

Join more than 70,000 authors publishing their insights on JD Supra

Start Publishing »

Rothwell, Figg, Ernst & Manbeck, P.C. on:

Reporters on Deadline

"My best business intelligence, in one easy email…"

Your first step to building a free, personalized, morning email brief covering pertinent authors and topics on JD Supra:
Sign Up Log in
*By using the service, you signify your acceptance of JD Supra's Privacy Policy.
Custom Email Digest
- hide
- hide